Clinical trial · Interventional
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study will be incorporated into another study.
Summary
Brief summary (as posted)
The purpose of this study is to collect data on the safety and effectiveness of 2nd generation designer T cells in patients with colorectal cancer. Designer T cells are prepared by collecting white blood cells from the participant, and then modifying these cells in the laboratory so that they recognize the tumor antigen (CEA). These modified cells are then given back into the participant so that they can attack and kill tumor cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gene Modified T Cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gene Modified T Cells
- description
- Modified T cells
- interventionNames
- Biological: Gene Modified T Cells
Primary outcomes (1)
- measure
- Determine the safety of using modified T cells by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).
- timeFrame
- 1 Month
Secondary outcomes (3)
- measure
- Tumor Response
- timeFrame
- 1 Month
- measure
- Pharmacokinetics
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must have cancer of the colon or rectum * Must have metastatic or unresectable locally advanced disease * Tumor must express CEA by tumor staining or by elevated serum CEA (\>10 ng/ml) * Must have measurable disease radiologically or by physical exam * Must have failed potentially curative standard therapy * Must be 18 years of age or older * Good performance status (PS 0-1) Exclusion Criteria: * Requiring systemic steroids * Serious medical conditions * Concurrent malignancies
References
Publications (0)
Data not yet available